Universal Health downgraded to Market Perform from Outperform at Raymond James

Raymond James downgraded Universal Health (UHS) to Market Perform from Outperform without a price target The firm has concerns about the company’s ability EBITDA guidance throughout 2026. The low end of EBITDA guidance implies 16% year-over-year normalized growth following a quarter of 12% normalized EBITDA decline, the analyst tells investors in a research note. Raymond James thinks the market will be “unconvinced about the implied inflection absent more support.”